Vanguard Group Inc. raised its stake in shares of Theravance Biopharma Inc (NASDAQ:TBPH) by 1.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,932,787 shares of the biopharmaceutical company’s stock after acquiring an additional 54,562 shares during the quarter. Vanguard Group Inc. owned approximately 6.94% of Theravance Biopharma worth $64,223,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. CWM Advisors LLC bought a new position in shares of Theravance Biopharma during the second quarter valued at $167,000. DekaBank Deutsche Girozentrale raised its holdings in shares of Theravance Biopharma by 21.9% in the first quarter. DekaBank Deutsche Girozentrale now owns 11,700 shares of the biopharmaceutical company’s stock valued at $337,000 after buying an additional 2,100 shares during the last quarter. Ibex Investors LLC raised its holdings in shares of Theravance Biopharma by 40.8% in the second quarter. Ibex Investors LLC now owns 45,225 shares of the biopharmaceutical company’s stock valued at $739,000 after buying an additional 13,102 shares during the last quarter. Virtus ETF Advisers LLC raised its holdings in shares of Theravance Biopharma by 77.4% in the second quarter. Virtus ETF Advisers LLC now owns 50,751 shares of the biopharmaceutical company’s stock valued at $829,000 after buying an additional 22,139 shares during the last quarter. Finally, Bank of Montreal Can raised its holdings in shares of Theravance Biopharma by 28,276.0% in the second quarter. Bank of Montreal Can now owns 103,856 shares of the biopharmaceutical company’s stock valued at $1,696,000 after buying an additional 103,490 shares during the last quarter. 84.16% of the stock is owned by institutional investors.
A number of analysts recently commented on TBPH shares. BidaskClub lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Friday. Piper Jaffray Companies reiterated a “buy” rating on shares of Theravance Biopharma in a research report on Monday, September 9th. Finally, Cantor Fitzgerald set a $55.00 price objective on Theravance Biopharma and gave the stock a “buy” rating in a research report on Friday, August 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $44.25.
Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.50. The company had revenue of $26.15 million for the quarter, compared to the consensus estimate of $13.92 million. As a group, equities analysts expect that Theravance Biopharma Inc will post -4.34 earnings per share for the current fiscal year.
About Theravance Biopharma
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.
Further Reading: Bear Market – How and Why They Occur
Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma Inc (NASDAQ:TBPH).
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.